Multivariate analysis (Cox regression) on the overall survival in patients with AML
| Variables . | Hazard ratio . | 95% confidence interval . | P value . |
|---|---|---|---|
| Non-M3 AML group | |||
| Age* | 2.623 | 1.693-4.062 | <.001 |
| WBC† | 2.414 | 1.517-3.841 | <.001 |
| Karyotype‡ | 3.317 | 1.578-6.972 | .002 |
| LGALS3§ | 1.736 | 1.133-2.662 | .011 |
| NPM1/FLT3-ITD|| | 0.337 | 0.157-0.723 | .005 |
| CEBPA¶ | 0.359 | 0.163-0.788 | .011 |
| AML1/RUNX1 | 2.017 | 1.073-3.789 | .029 |
| MLL-PTD | 3.155 | 1.207-8.245 | .019 |
| WT1 | 2.704 | 1.385-5.279 | .004 |
| Normal karyotype group | |||
| Age* | 3.389 | 1.757-6.536 | <.001 |
| WBC† | 3.01 | 1.56-5.808 | .001 |
| LGALS3§ | 2.737 | 1.434-5.225 | .002 |
| NPM1/FLT3-ITD|| | 0.337 | 0.141-0.806 | .015 |
| CEBPA¶ | 0.257 | 0.096-0.687 | .007 |
| WT1 | 3.208 | 1.228-8.378 | .017 |
| Variables . | Hazard ratio . | 95% confidence interval . | P value . |
|---|---|---|---|
| Non-M3 AML group | |||
| Age* | 2.623 | 1.693-4.062 | <.001 |
| WBC† | 2.414 | 1.517-3.841 | <.001 |
| Karyotype‡ | 3.317 | 1.578-6.972 | .002 |
| LGALS3§ | 1.736 | 1.133-2.662 | .011 |
| NPM1/FLT3-ITD|| | 0.337 | 0.157-0.723 | .005 |
| CEBPA¶ | 0.359 | 0.163-0.788 | .011 |
| AML1/RUNX1 | 2.017 | 1.073-3.789 | .029 |
| MLL-PTD | 3.155 | 1.207-8.245 | .019 |
| WT1 | 2.704 | 1.385-5.279 | .004 |
| Normal karyotype group | |||
| Age* | 3.389 | 1.757-6.536 | <.001 |
| WBC† | 3.01 | 1.56-5.808 | .001 |
| LGALS3§ | 2.737 | 1.434-5.225 | .002 |
| NPM1/FLT3-ITD|| | 0.337 | 0.141-0.806 | .015 |
| CEBPA¶ | 0.257 | 0.096-0.687 | .007 |
| WT1 | 3.208 | 1.228-8.378 | .017 |
Only variables with P value less than .05 in univariate analysis were incorporated into the multivariate Cox proportional hazard regression analysis.
Age older than 50 y relative to age 50 y or younger.
WBC greater than 50 000/μL vs less than or equal to 50 000/μL.
Unfavorable cytogenetics versus others. Eight patients without chromosome data were not included in the analysis.
Higher LGALS3 expression vs lower LGALS3 expression.
NPM1+/FLT3-ITD− vs other subtypes.
CEBPAdouble-mut vs other subtypes.